925 related articles for article (PubMed ID: 27966046)
1. Differentiated Thyroid Cancer lymph-node relapse. Role of adjuvant radioactive iodine therapy after lymphadenectomy.
Piccardo A; Puntoni M; Bottoni G; Treglia G; Foppiani L; Bertoli M; Catrambone U; Arlandini A; Dib B; Altrinetti V; Massollo M; Bossert I; Cabria M; Bertagna F; Giovanella L
Eur J Nucl Med Mol Imaging; 2017 Jun; 44(6):926-934. PubMed ID: 27966046
[TBL] [Abstract][Full Text] [Related]
2. Relapse-free survival after adjuvant radioactive iodine therapy in patients with differentiated thyroid carcinoma with a microscopically positive tumor margin.
Watanabe K; Igarashi T; Uchiyama M; Ojiri H
Ann Nucl Med; 2020 Dec; 34(12):920-925. PubMed ID: 32940889
[TBL] [Abstract][Full Text] [Related]
3. Effect of prophylactic central compartment neck dissection on serum thyroglobulin and recommendations for adjuvant radioactive iodine in patients with differentiated thyroid cancer.
Wang TS; Evans DB; Fareau GG; Carroll T; Yen TW
Ann Surg Oncol; 2012 Dec; 19(13):4217-22. PubMed ID: 23010732
[TBL] [Abstract][Full Text] [Related]
4. Undetectable thyroglobulin after total thyroidectomy in patients with low- and intermediate-risk papillary thyroid cancer--is there a need for radioactive iodine therapy?
Ibrahimpasic T; Nixon IJ; Palmer FL; Whitcher MM; Tuttle RM; Shaha A; Patel SG; Shah JP; Ganly I
Surgery; 2012 Dec; 152(6):1096-105. PubMed ID: 23158181
[TBL] [Abstract][Full Text] [Related]
5. Ongoing risk stratification for differentiated thyroid cancer (DTC) - stimulated serum thyroglobulin (Tg) before radioiodine (RAI) ablation, the most potent risk factor of cancer recurrence in M0 patients.
Krajewska J; Jarząb M; Czarniecka A; Roskosz J; Kukulska A; Handkiewicz-Junak D; Puch Z; Wygoda Z; Paliczka-Cieślik E; Kropińska A; Gubała E; Jurecka-Lubieniecka B; Jarząb B
Endokrynol Pol; 2016; 67(1):2-11. PubMed ID: 26884109
[TBL] [Abstract][Full Text] [Related]
6. Long-term course and predictive factors of elevated serum thyroglobulin and negative diagnostic radioiodine whole body scan in differentiated thyroid cancer.
Alzahrani AS; Mohamed G; Al Shammary A; Aldasouqi S; Abdal Salam S; Shoukri M
J Endocrinol Invest; 2005 Jun; 28(6):540-6. PubMed ID: 16117196
[TBL] [Abstract][Full Text] [Related]
7. Total thyroidectomy and adjuvant radioiodine treatment independently decrease locoregional recurrence risk in childhood and adolescent differentiated thyroid cancer.
Handkiewicz-Junak D; Wloch J; Roskosz J; Krajewska J; Kropinska A; Pomorski L; Kukulska A; Prokurat A; Wygoda Z; Jarzab B
J Nucl Med; 2007 Jun; 48(6):879-88. PubMed ID: 17536106
[TBL] [Abstract][Full Text] [Related]
8. Utility of adjuvant radioactive iodine therapy after reoperation in papillary thyroid carcinoma with cervical lymph node recurrence.
Zhang Y; Zhu X; Fan Q; Huang Q; Tu Y; Jiang L; Zhang Z; Chen J
Jpn J Radiol; 2023 Oct; 41(10):1148-1156. PubMed ID: 37266825
[TBL] [Abstract][Full Text] [Related]
9. Postoperative radioactive iodine-131 ablation is not necessary among patients with intermediate-risk differentiated thyroid carcinoma: a population-based study.
Zhang H; Cai Y; Zheng L; Zhang Z; Jiang N
Hell J Nucl Med; 2017; 20(1):3-10. PubMed ID: 28315902
[TBL] [Abstract][Full Text] [Related]
10. Radioactive iodine (RAI) therapy for distantly metastatic differentiated thyroid cancer (DTC) in juvenile versus adult patients.
Kammori M; Fukumori T; Sugishita Y; Hoshi M; Shimizu K; Yamada T
Endocr J; 2015; 62(12):1067-75. PubMed ID: 26424174
[TBL] [Abstract][Full Text] [Related]
11. Clinical outcome in differentiated thyroid carcinoma and microcarcinoma.
Lupoli R; Cacciapuoti M; Tortora A; Barba L; Verde N; Romano F; Vastarella M; Fonderico F; Masone S; Milone M; Lupoli G; Lupoli GA
Int J Surg; 2014; 12 Suppl 1():S148-51. PubMed ID: 24859408
[TBL] [Abstract][Full Text] [Related]
12. Serum thyroglobulin level after radioiodine therapy (Day 3) to predict successful ablation of thyroid remnant in postoperative thyroid cancer.
Kim YI; Im HJ; Paeng JC; Cheon GJ; Kang KW; Lee DS; Joon Park D; Park YJ; Chung JK
Ann Nucl Med; 2015 Feb; 29(2):184-9. PubMed ID: 25404419
[TBL] [Abstract][Full Text] [Related]
13. Impact of early vs late postoperative radioiodine remnant ablation on final outcome in patients with low-risk well-differentiated thyroid cancer.
Tsirona S; Vlassopoulou V; Tzanela M; Rondogianni P; Ioannidis G; Vassilopoulos C; Botoula E; Trivizas P; Datseris I; Tsagarakis S
Clin Endocrinol (Oxf); 2014 Mar; 80(3):459-63. PubMed ID: 23895145
[TBL] [Abstract][Full Text] [Related]
14. Differentiated thyroid cancer. Impact of adjuvant external radiotherapy in patients with perithyroidal tumor infiltration (stage pT4).
Farahati J; Reiners C; Stuschke M; Müller SP; Stüben G; Sauerwein W; Sack H
Cancer; 1996 Jan; 77(1):172-80. PubMed ID: 8630926
[TBL] [Abstract][Full Text] [Related]
15. Comparison of Survival Outcomes Following Postsurgical Radioactive Iodine Versus External Beam Radiation in Stage IV Differentiated Thyroid Carcinoma.
Yang Z; Flores J; Katz S; Nathan CA; Mehta V
Thyroid; 2017 Jul; 27(7):944-952. PubMed ID: 28446057
[TBL] [Abstract][Full Text] [Related]
16. Transient early increase in thyroglobulin levels post-radioiodine ablation in patients with differentiated thyroid cancer.
Stevic I; Dembinski TC; Pathak KA; Leslie WD
Clin Biochem; 2015 Jul; 48(10-11):658-61. PubMed ID: 25895485
[TBL] [Abstract][Full Text] [Related]
17. Even without additional therapy, serum thyroglobulin concentrations often decline for years after total thyroidectomy and radioactive remnant ablation in patients with differentiated thyroid cancer.
Padovani RP; Robenshtok E; Brokhin M; Tuttle RM
Thyroid; 2012 Aug; 22(8):778-83. PubMed ID: 22780333
[TBL] [Abstract][Full Text] [Related]
18. Focus on high-risk DTC patients: high postoperative serum thyroglobulin level is a strong predictor of disease persistence and is associated to progression-free survival and overall survival.
Piccardo A; Arecco F; Puntoni M; Foppiani L; Cabria M; Corvisieri S; Arlandini A; Altrinetti V; Bandelloni R; Orlandi F
Clin Nucl Med; 2013 Jan; 38(1):18-24. PubMed ID: 23242039
[TBL] [Abstract][Full Text] [Related]
19. Treatment for microcarcinoma of the thyroid--clinical experience.
Küçük NO; Tari P; Tokmak E; Aras G
Clin Nucl Med; 2007 Apr; 32(4):279-81. PubMed ID: 17413573
[TBL] [Abstract][Full Text] [Related]
20. Low activity versus high activity: noninferior response to radioiodine therapy in differentiated patients with extrathyroid extension.
Wang C; Zhao T; Li H; Gao W; Lin Y
Nucl Med Commun; 2017 May; 38(5):366-371. PubMed ID: 28362717
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
